Douglas W. Blayney, MD @BlayneyDouglas @StanfordMed @BeyondSpringInc #ASCO22 #OncoTwitter @oncoalert  Phase 3 Real-world Effectiveness Of G-CSF In Pts with BC

Douglas W. Blayney, MD @BlayneyDouglas @StanfordMed @Beyo...

2 months
85 Views
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Douglas W. Blayney, MD, FASCO, Clinical researcher and breast oncologist, Professor of Medicine at Stanford University. In this video, he speaks about the ASCO 2022 Abstract - Real-world effectiveness of prophylactic granulocyte colony-stimulating factor (G-CSF) early (week 1) and late (weeks 2-3) in the cycle for the prevention of febrile neutropenia (FN) among patients (pts) with breast cancer (BC) after high FN–risk chemotherapy (chemo).


Overview:

The major goal of this study is to compare the percentage of patients with DSN =0 in patients treated with:

Docetaxel, doxorubicin, and cyclophosphamide (TAC) plus pegfilgrastim versus TAC + plinabulin/pegfilgrastim combo

Severe neutropenia is defined as an absolute neutrophil count (ANC) of 0.5109/L.

The chemotherapy in this study will consist of docetaxel, doxorubicin, and cyclophosphamide (TAC).